Biotinylated Human CA125/MUC16 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Biotinylated Human CA125/MUC16 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
It contains Gly12660-Met12923 [Accession | Q8WXI7].

分子量大小(Molecular Weight)

The protein has a predicted MW of 31.3 kDa. Due to glycosylation, the protein migrates to 52-80 kDa based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Biotinylated Human CA125 on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%.

ELISA Data

Immobilized Human MSLN, hFc Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human CA125, His Tag with the EC50 of 0.1μg/ml determined by ELISA (QC Test).

背景(Background)

MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy.Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN.

分子别名(Synonyms)

CA125; CA-125; CA125MUC-16; FLJ14303; MUC16

文献(References)

(1)Das S , Batra S K. Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy[J]. Cancer Research, 2015:0008-5472.CAN-15-1050.

(2)Rao T D , Park K J , Smith-Jones P , et al. Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16[J]. Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry, 2010, 18(5):462-472.